Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Duodenal Mucosa Responses to Endoscopic Food Challenges in Patients With Inflammatory Bowel Disease and Irritable Bowel Syndrome With Self-reported Food Intolerances: A Feasibility Study (DRFC)

12. november 2026 oppdatert av: David Armstrong, McMaster University

Duodenal Responses to Food Challenges in Patients With Self-reported Food Intolerances: a Feasibility Study

The goal of this study is to investigate the feasibility of using intravenous fluorescein during a standard endoscopy-along with a laser to activate it and an optical filter-to identify changes in the duodenal mucosa after a controlled food challenge in individuals with IBD and IBS who experience food intolerances. The main questions it aims to answer are:

  • Is this technique feasible approach to assess food intolerances in patients with IBD and IBS?
  • Does patients with IBD and IBS exhibit acute tissue changes upon exposure to specific food antigens?

Researches will compare the food antigen to a placebo solution (saline solution without an antigen) to see if the reaction in the tissue is different.

Participants will:

  • Answer questionnaires.
  • Provide a blood and stool sample.
  • Take an allergy test.
  • Undergo an upper endoscopy.

Studieoversikt

Detaljert beskrivelse

This is a prospective, double-arm, randomized feasibility study. This study will recruit patients with Inflammatory Bowel Disease (IBD) in remission and patients with Irritable Bowel Syndrome (IBS), who self-report food intolerances. All participants will undergo an upper endoscopy with the administration of a food challenge solution (cow's milk protein or placebo), intravenous fluoresceine administration, biopsies and fluid collection.

Upon signing informed consent, participants will be enrolled in the study. Following enrollment, participants will be randomized in a 2:1 ratio to receive either a food challenge with a cow's milk protein solution or a placebo solution during the upper endoscopy, which will occur in visit 3.

During the first visit, participants will complete questionnaires covering demographics, medical history, gastrointestinal symptoms (using the Gastrointestinal Symptoms Rating Scale), and food intolerances. Blood samples will be collected from all participants, and IBD patients will additionally provide stool samples for fecal calprotectin measurement.

In the second visit, participants will be evaluated by an experienced allergologist, and a skin prick test will be conducted to rule out an allergy to cow's milk protein.

After completing these initial evaluations, participants will be scheduled for visit 3. In preparation for this visit, participants will be instructed to avoid consuming any products containing cow's milk for five days prior. During visit 3, an upper endoscopy will be performed. Through the endoscope's working channel, either a cow's milk protein solution or a placebo solution will be delivered to the third portion of the duodenum. Additionally, eight biopsies and a fluid sample will be collected from this area. A permeability test will also be performed using intravenous fluorescein, and the procedure will be recorded on video.

Following the third visit, a follow-up phone call will be conducted to assess any symptoms that participants may have experienced post-procedure.

Studietype

Intervensjonell

Registrering (Antatt)

12

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Ontario
      • Hamilton, Ontario, Canada, L8S 4K1
        • McMaster University Medical Centre
        • Hovedetterforsker:
          • David Armstrong, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Confirmed diagnosis of IBD (UC or CD) and under clinical remission for at least 3 months, OR confirmed diagnosis of IBS (any subtype) by Rome IV criteria.
  • Report having one or more food intolerance.
  • Able to provide informed consent.

Exclusion Criteria:

  • Presence of a known food allergy.
  • Presence of serum IgE positivity or a positive skin-prick test to cow's milk.
  • Known allergy to fluorescein.
  • Diagnosis of celiac disease.
  • Positive IgA TTG antibodies.
  • Pregnancy or breastfeeding.
  • Presence of a contraindication for an upper endoscopy.
  • History of surgery involving the upper gastrointestinal tract.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Cow's milk protein solution

A solution with 5 mL cow's milk protein fraction mixed with 50% sterile water applied onto the duodenal mucosa one time during an upper endoscopy.

Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis

Andre navn:
  • EGD
  • esophagogastroduodenoskopi
Placebo komparator: Placebo solution

A solution with 18 mL sterile water + 2 mL simethicone applied onto the duodenal mucosa one time during an upper endoscopy.

Participants will undergo an upper gastrointestinal endoscopy under conscious sedation. Standard monitoring will be used, and a high-definition video system will record the procedure. A Fuji colonoscope fitted with a transparent distal cap and optical filter will guide the examination up to the proximal jejunum. Upon reaching the duodenum (D3), 5 mL of 10% fluorescein and 40 mg methylscopolamine will be injected intravenously. Immediately after, either a cow's milk protein solution or a placebo solution will be applied to the duodenal mucosa via the endoscope channel. A laser will excite the fluorescein, and real-time video will be recorded. Duodenal fluid (1-1.5 mL) will be collected with an ERCP catheter, and eight biopsies will be obtained for analysis

Andre navn:
  • EGD
  • esophagogastroduodenoskopi

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Procedure completition
Tidsramme: From the start of the endoscopy up to 10 minutes after the food challenge

Successful completion of the procedure including sample collection, administration of the food challenge, and development of a reaction in the duodenal mucosa. A positive reaction in the mucosa will be defined by the presence of intraepithelial lymphocytes >25/100 epithelial cells.

From the start of the endoscopy up to 10 minutes after the food challenge

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. februar 2027

Primær fullføring (Antatt)

31. desember 2027

Studiet fullført (Antatt)

31. mars 2028

Datoer for studieregistrering

Først innsendt

12. november 2026

Først innsendt som oppfylte QC-kriteriene

12. november 2026

Først lagt ut (Faktiske)

19. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere